menu
    • menu
    [{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Unitaid"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Not Applicable"},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"Steroid 5-alpha reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometria Institute \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"All India Institutes of Medical Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"All India Institutes of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"All India Institutes of Medical Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"All India Institutes of Medical Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mountain Valley MD \/ Not Applicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"The American College of Medical Toxicology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The American College of Medical Toxicology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"The American College of Medical Toxicology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The American College of Medical Toxicology \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Medicines Patent Pool","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Medicines Patent Pool"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Unitaid"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Senores Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Ivermectin

    Menu

    Ivermectin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Senores Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories and Senores Pharmaceuticals Launch Ivermectin Tablets in US

                            Details : Stromectol-Generic (ivermectin) is a glutamate-gated chloride channel modulator, small molecule drug candidate, which is indicated for the treatment of patients with strongyloidiasis & onchocerciasis.

                            Brand Name : Stromectol-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 26, 2024

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Senores Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Unitaid

                            Deal Size : $6.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

                            Details : The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.

                            Brand Name : mdc-STM

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 08, 2024

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Unitaid

                            Deal Size : $6.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MedinCell Announces Positive Results For The SAIVE Clinical Study In Prevention Of Covid-19 Infection In A Con...

                            Details : The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology,...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : The Medicines Patent Pool

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of I...

                            Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.

                            Brand Name : mdc-STM

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 13, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : The Medicines Patent Pool

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Zydus Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Gets USFDA Nod for Ivermectin Cream

                            Details : Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.

                            Brand Name : Ivermectin-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lyndra Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Lyndra Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a...

                            Details : Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.

                            Brand Name : LYN-163

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MedinCell: Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE

                            Details : The objective of MedinCell’s mdc-TTG program is to protect humans from Covid-19 and its variants with a long-acting injection of Ivermectin, SAIVE aims at validating the efficacy in prophylaxis against Covid-19 of administration of Ivermectin in oral d...

                            Brand Name : mdc-TTG

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The American College of Medical Toxicology

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            The American College of Medical Toxicology

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            American College of Medical Toxicology Reports Data on Adverse Effects and Toxicity from Unapproved Use of Ive...

                            Details : Ivermectin is FDA-approved for prescription use in humans as an antiparasitic drug to treat conditions including intestinal strongyloidiasis and onchocerciasis or river blindness.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 20, 2021

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            MedinCell

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MedinCell’s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development

                            Details : The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.

                            Brand Name : mdc-STM

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 14, 2021

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mountain Valley MD

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mountain Valley MD

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested Wi...

                            Details : A single dose of 2.5 milligrams per kilogram of Ivectosol™ was effective at interfering with viral replication and driving viral clearance of the B.1.1.7 COVID-19 variant.

                            Brand Name : Ivectosol

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2021

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth